🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Current Issue: Metastatic Poorly Differentiated Thyroid Cancer With Heterogeneous Distribution of 18F-FDG, 68Ga-DOTATATE, and 68Ga-PSMA on PET/CT dlvr.it/S357cv

Olha ai Margaret Masukawa

Current Issue: Diffuse Subcutaneous Metabolic Activity in Post Bone Marrow Transplant Hodgkin Lymphoma dlvr.it/S414Lb

EANM 2021 in 7 days, everywhere in the Universe

EANM 2021 in 5 days … it should have been in Germany but will be virtual @officialEANM #EANM21

Great achievement prof. Stefano Fanti. Outstanding EANM 2021 congress!

How to deal with intra-patient and inter-patient PSMA heterogeneity? Disruptive talk about #PSMA immunohistochemistry and #PET in #prostatecancer at #EANM21 by Daniela A. Ferraro @officialEANM

PSMA Expression Assessed by PET Imaging Is a Required Biomarker for Selecting Patients for Any PSMA-Targeted Therapy jnm.snmjournals.org/content/62/11/… Johannes Czernin Michael Hofman SNMMI Thomas Hope

TheraP - Lutetium PSMA shows greater PSA response rates, less adverse events and superior PFS to cabazitaxel. Similar OS. Higher responses if PSMA SUVmax >10. Great work ANZUP Michael Hofman

18F-PSMA-11 Versus 68Ga-PSMA-11 for staging primary and recurrent PCa: A Prospective Double-blind Randomised Cross-over Trial. Conclusion: 18F-PSMA-11 is noninferior to 68Ga-PSMA-11! bit.ly/3mxUiGm

What will the future hold for molecular imaging of neurodegenerative disorders? Read Barthel, Villemagne, and Drzezga’s take: ow.ly/2OhN50JqipM #MedicalImaging #NuclearMedicine #Dementia

A great honor.

Now starting: #eanm

Now starting: #eanm

#EAU2024 PSMA reporting news!!! “COPRA is now SPARC! Standardized PSMA PET Analysis and Reporting Consensus: SPARC. Time to standardize the way we report PSMA PET” by Ken Herrmann linkedin.com/posts/ken-herr…

Novartis confirms plans to file for Pluvicto® pre-taxane label expansion in H2 2024 based on latest data from Phase III PSMAfore study | Novartis ⁦OncoAlert⁩ ⁦GU Cast | Urology podcast!⁩ ⁦Advanced Prostate Cancer Consensus Conference⁩ ⁦GUARD Consortium⁩ novartis.com/news/novartis-…